Logo image of PPD

PPD Inc (PPD) Stock Fundamental Analysis

NASDAQ:PPD - Nasdaq - Common Stock

47.28  -0.03 (-0.06%)

After market: 47.48 +0.2 (+0.42%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PPD. PPD was compared to 56 industry peers in the Life Sciences Tools & Services industry. PPD may be in some trouble as it scores bad on both profitability and health. PPD is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PPD was profitable.
PPD Yearly Net Income VS EBIT VS OCF VS FCFPPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 100M 200M 300M 400M 500M

1.2 Ratios

Industry RankSector Rank
ROA 5.18%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PPD Yearly ROA, ROE, ROICPPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 10 -10 -20

1.3 Margins

Industry RankSector Rank
OM 11.39%
PM (TTM) 6.19%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPD Yearly Profit, Operating, Gross MarginsPPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 10 20 30 40

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for PPD has been increased compared to 1 year ago.
Compared to 1 year ago, PPD has an improved debt to assets ratio.
PPD Yearly Shares OutstandingPPD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 100M 200M 300M
PPD Yearly Total Debt VS Total AssetsPPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2B 4B 6B

2.2 Solvency

PPD has an Altman-Z score of 2.22. This is not the best score and indicates that PPD is in the grey zone with still only limited risk for bankruptcy at the moment.
PPD has a Debt/Equity ratio of -9.91. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -9.91
Debt/FCF N/A
Altman-Z 2.22
ROIC/WACCN/A
WACCN/A
PPD Yearly LT Debt VS Equity VS FCFPPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 2B -2B 4B

2.3 Liquidity

A Current Ratio of 1.23 indicates that PPD should not have too much problems paying its short term obligations.
PPD has a Quick Ratio of 1.23. This is a normal value and indicates that PPD is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
PPD Yearly Current Assets VS Current LiabilitesPPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 500M 1B 1.5B 2B 2.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.29% over the past year.
PPD shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.79% yearly.
PPD shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.71%.
PPD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.97% yearly.
EPS 1Y (TTM)39.29%
EPS 3Y-20.19%
EPS 5Y-4.79%
EPS Q2Q%43.33%
Revenue 1Y (TTM)34.71%
Revenue growth 3Y15.98%
Revenue growth 5Y14.97%
Sales Q2Q%26.5%

3.2 Future

Based on estimates for the next years, PPD will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.02% on average per year.
PPD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.64% yearly.
EPS Next Y37.26%
EPS Next 2Y24.89%
EPS Next 3Y21.23%
EPS Next 5Y18.02%
Revenue Next Year31.13%
Revenue Next 2Y17.85%
Revenue Next 3Y14.86%
Revenue Next 5Y11.64%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PPD Yearly Revenue VS EstimatesPPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
PPD Yearly EPS VS EstimatesPPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

PPD is valuated quite expensively with a Price/Earnings ratio of 30.31.
PPD is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.68, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 25.69, PPD can be considered very expensive at the moment.
PPD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.50, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 30.31
Fwd PE 25.69
PPD Price Earnings VS Forward Price EarningsPPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.7
PPD Per share dataPPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PPD's earnings are expected to grow with 21.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y24.89%
EPS Next 3Y21.23%

More info and screens

0

5. Dividend

5.1 Amount

PPD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PPD Inc

NASDAQ:PPD (12/7/2021, 8:16:56 PM)

After market: 47.48 +0.2 (+0.42%)

47.28

-0.03 (-0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners21.86%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap17.00B
Analysts52.94
Price Target48.25 (2.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 30.31
Fwd PE 25.69
P/S 2.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 20.7
EPS(TTM)1.56
EY3.3%
EPS(NY)1.84
Fwd EY3.89%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS16.35
BVpS-1.18
TBVpSN/A
PEG (NY)0.81
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 11.39%
PM (TTM) 6.19%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity -9.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z 2.22
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.29%
EPS 3Y-20.19%
EPS 5Y-4.79%
EPS Q2Q%43.33%
EPS Next Y37.26%
EPS Next 2Y24.89%
EPS Next 3Y21.23%
EPS Next 5Y18.02%
Revenue 1Y (TTM)34.71%
Revenue growth 3Y15.98%
Revenue growth 5Y14.97%
Sales Q2Q%26.5%
Revenue Next Year31.13%
Revenue Next 2Y17.85%
Revenue Next 3Y14.86%
Revenue Next 5Y11.64%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A